• Revenue: $60 million, a 16% decline from $71 million in the same period last year.
• Gross Profit Margin: 29.1%, an 80 basis point improvement year-over-year and up 270 basis points sequentially.
• General and Administrative Expenses: $10.5 million, a 12.3% decrease from $12 million last year.
• Advertising Expenses: $4.6 million, a 20% reduction from $5.5 million last year.
• Net Income: $2.3 million or $0.11 per diluted share, compared to $0.7 million or $0.03 per diluted share last year.
• Adjusted EBITDA: $2.1 million, compared to $3.4 million in the prior year period.
• Cash and Cash Equivalents: $52 million with no debt as of September 30, 2024.
• New Customers: Approximately 77,000 new customers this quarter.

• Warning! GuruFocus has detected 3 Warning Signs with PETS.

Release Date: November 06, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• PetMed Express Inc (NASDAQ:PETS) improved its gross margin year over year and sequentially, achieving a $3.6 million sequential increase in adjusted EBITDA.
• The company successfully reduced general and administrative expenses, contributing to a $5 million annualized savings target.
• PetMed Express Inc (NASDAQ:PETS) enhanced its customer service, achieving a 4.5-star customer rating on Trustpilot, up from 1.5 stars.
• The company relaunched its website with a modern UX/UI design, improving the shopping experience and planning to introduce AI-enhanced features.
• PetMed Express Inc (NASDAQ:PETS) strengthened its relationship with veterinarians, leading to a 9% increase in user engagement through redesigned prescription flow.

Negative Points

• PetMed Express Inc (NASDAQ:PETS) experienced a 16% decline in sales compared to the same period last year, reflecting consumer pressure and reduced marketing investment.
• The company faced a challenging promotional environment, with customers increasingly seeking discounts and promotional codes.
• There is a noted decrease in customer compliance with medication and reduced frequency of veterinary visits, impacting sales.
• Despite improvements, the company is still in the early stages of its transformation, indicating ongoing challenges in achieving its strategic goals.
• PetMed Express Inc (NASDAQ:PETS) anticipates a lower gross margin in upcoming quarters due to increased promotional activities.

Q & A Highlights

Q: How should we think about the growth rate for the second half of the year given the consecutive quarters of double-digit revenue decline? A: Robyn DElia, Chief Financial Officer, explained that the company intentionally reduced marketing spend but is now focusing on customer acquisition in the third and fourth quarters. They are pushing marketing efforts to drive new customer growth, with a substantial increase expected from Q3 to Q4.

Q: Should the current gross margin be considered sustainable for the rest of the year? A: Robyn DElia noted that while the gross margin improved by 80 basis points, the company is entering a heavier promotional period. Historically, Q3 has been a lower quarter for gross margin, and they plan to invest more heavily in marketing.

Q: What macro dynamics are impacting the business, and how are customer behaviors changing? A: Robyn DElia highlighted that customers are under financial pressure, seeking more promotional codes and discounts. There is also a reduction in compliance with medication and frequency of veterinary visits, impacting sales. The company is focusing on new customer acquisition to counter these trends.

Q: Can you elaborate on the marketing investments and their expected impact? A: Robyn DElia mentioned that marketing efforts will focus on both brand awareness and transactional activities, with key campaigns planned for Q3 through the holidays. The aim is to drive new customer acquisition and re-engage lapsed customers.

Q: How is PetMed Express addressing operational excellence and customer experience improvements? A: Sandra Campos, CEO, discussed initiatives such as improving the customer call center, enhancing technology infrastructure, and redesigning the prescription flow. These efforts have led to better customer ratings and increased user engagement.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.